The analgesic potential of clostridial neurotoxin derivatives

Bibliography

• BLAST J, CHAPMAN ER, LINK E et al: Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature (1993) 365:160–163.
   PubMed Web of Science ®Google Scholar
• •First paper to describe the cleavage of a SNARE protein as the mechanistic basis of clostridial neurotoxin inhibition of neurotransmitter release.
   Google Scholar
• MONTECUCCO C, SCHIAVO G: Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol (1994) 13(1):1–8.
   PubMed Web of Science ®Google Scholar
• SCHIAVO G, MATTEOLI M, MONTECUCCO C: Neurotoxins affecting neuroexocytosis. Physiol. Rev. (2000) 80:717–766.
   PubMed Web of Science ®Google Scholar
• SCOTT AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology (1980) 87:1044–1049.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS J, CARRUTHERS A: Botox: beyond wrinkles. Clin. Dermatol (2004) 22:89–93.
   PubMed Web of Science ®Google Scholar
• •Good, clear review of recent developments in the therapeutic use of botulinum neurotoxins.
   Google Scholar
• CORDIVARI C, MISRA VP, CATANIA S, LEES AJ: New therapeutic indications for botulinum toxins. Mov. Disord. (2004) 19(8):S157–S161.
   PubMedGoogle Scholar
• PANICKER JN, MUTHANE UB: Botulinum toxins: Pharmacology and its current therapeutic evidence for use. Neurology India (2003) 51(4):455–460.
   PubMed Web of Science ®Google Scholar
• THANT Z-S, TAN E-K: Emerging therapeutic applications of botulinum toxin. Med. Sri. Monit. (2003) 9(2):RA40-RA48.
   Google Scholar
• •A very thorough review of emerging clinical uses of botulinum neurtoxins.
   Google Scholar
• RAJ PP: Botulinum toxin therapy in pain management. Anesthesiology Clin. N Am. (2003) 21:715–731.
   PubMedGoogle Scholar
• •A good review of the use of botulinum neurotoxins for pain management in pain syndromes resulting from neuromuscular disorders.
   Google Scholar
• ROYAL M: Botulinum toxins in pain management. Phys. Med. Rehabil Clin. N Am. (2003) 14:805–820.
   PubMedGoogle Scholar
• •A very thorough discussion of the use of botulinum neurotoxins in myofascial pain syndrome.
   Google Scholar
• ARGOFF CE: The use of botulinum toxins for chronic pain and headaches. Curr. Treat. Options Neurol (2003) 5:483–492.
   PubMedGoogle Scholar
• ••A lot of detail on the clinical use ofbotulinum neurotoxin in specific pain syndromes.
   Google Scholar
• ARGOFF CE: A focused review on the use of botulinum toxins for neuropathic pain. ClinT Path (2002) 18:S177–S181.
   Web of Science ®Google Scholar
• AREZZO JC: Possible mechanisms for the effects of botulinum toxin on pain. Path (2002) 18:S125–S132.
   Google Scholar
• ••A clear and detailed review of the currentknowledge regarding possible mechanisms of action underlying the ability of botulinum neurotoxins to effect pain relief in a variety of clinical conditions.
   Google Scholar
• MENSE S: Neurobiological basis for the use of botulinum toxin in pain therapy. Neurol (2004) 251 (Suppl.
   Google Scholar
• PURKISS JR, WELCH MJ, DOWARD S, FOSTER KA: Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem. Pharmacol (2000) 59:1403–1406.
   PubMed Web of Science ®Google Scholar
• WELCH MJ, PURKISS JR, FOSTER KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicology (2000) 38:245–258.
   Google Scholar
• ISHIKAWA H, MITSUI Y, YOSHITOMI T et al: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpnj Ophthalmol. (2000) 44:106–109.
   Web of Science ®Google Scholar
• AOKI KR: Pharmacology and immunology of botulinum toxin serotypes. Neurol. (2001) 248\(Suppl. 1):3–10.
   Google Scholar
• BORODIC GE, ACQUADRO M, JOHNSON EA: Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin. Investig. Drugs (2001) 10:1531–1544.
   PubMed Web of Science ®Google Scholar
• AOKI KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache (2003) 43\(Suppl. 1):59–515.
   Google Scholar
• CUT M, KHANIJOU S, RUBINO, AOKI KR: Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain (2004) 107(1-2):125–133.
   PubMed Web of Science ®Google Scholar
• ••An important primary research papergiving the first demonstration of a direct analgesic effect of BoNT/A in a standard animal model of inflammatory pain, and thereby providing insights into the clinical effectiveness of botulinum neurotoxins in pain relief.
   Google Scholar
• MORENILLA-PALAO C, PLANELLS-CASES R, GARCIA-SANZ N, FERRER-MONTIEL A: Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J. Biol. Chem. (2004) 279:25665–25672.
   PubMed Web of Science ®Google Scholar
• ••An exciting primary research paperreporting an effect of botulinum neurotoxin on the upregulation of cell surface receptors in nociceptive afferent neurons, which may play a role in the analgesic activity of the neurotoxins additional to their effect on neurotransmitter release.
   Google Scholar
• SIMPSON LL: Molecular pharmacology of botulinum toxin and tetanus toxin. Ann. Rev Pharmacol Toxicol (1986) 26:427–453.
   PubMed Web of Science ®Google Scholar
• HALPERN JL, LOFTUS A: Characterisation of the receptor binding domain of tetanus toxin. I Biol. Chem. (1993) 268:11188–11192.
   Web of Science ®Google Scholar
• SHONE CC, HAMBLETON P, MELLING J: Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity. Eur. Biochem. (1985) 151:75–82.
   Google Scholar
• SHONE CC, HAMBLETON P, MELLING J: A 50-kDa fragment from the NH2-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles. Eur. Biochem. (1987) 167:175–180.
   PubMedGoogle Scholar
• LACY B, TEPP W, COHEN AC et al: Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. (1998) 5:898–902.
   PubMedGoogle Scholar
• SWAMINATHAN S, ESWARAMOORTHYS: Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. (2000) 7:693–699.
   PubMedGoogle Scholar
• UMLAN TC, WINGERT LM, SWAMINATHAN S et al.: Structure of the receptor binding fragment HC of tetanus neurotoxin. Nat. Struct. Biol. (1997) 4:788–792.
   PubMedGoogle Scholar
• HANSON MA, STEVENS RC: Structural view of botulinum neurotoxin in numerous functional states. In: Scientific and Therapeutic Aspects of Botulinum Toxin. MF Brin, J Jankovic, M Hallett (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2002):11–27.
   Google Scholar
• •A comprehensive review of structural studies, including X-ray crystallographic, on the clostridial neurotoxins.
   Google Scholar
• SWAMINATHAN S, ESWARAMOORTHY S: Crystal structure of Clostridium botulinum neurotoxin serotype B. In: Scientific and Therapeutic Aspects of Botulinum Toxin. MF Brin, J Jankovic, M Hallett (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2002):29–39.
   Google Scholar
• •A clear and informative review of X-ray crystalographic studies of BoNT/13 structure.
   Google Scholar
• SUTTON JM, SPAVEN L, SILMAN N et al: The receptor binding domains of clostridial neurotoxins. In: Scientific and Therapeutic Aspects of Botulinum Toxin. MF Brin, J Jankovic, M Hallett (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2002):41–48.
   Google Scholar
• ••A very thorough review of the currentknowledge concerning the binding domains of clostridial neurotoxins.
   Google Scholar
• CHADDOCK JA, HERBERT MH, LING RJ et al.: Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr. Purif (2002) 25:219–228.
   PubMed Web of Science ®Google Scholar
• CHADDOCK JA, PURKISS JR, FRIIS LM et al: Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect. Immun. (2000) 68:2587–2593.
   PubMed Web of Science ®Google Scholar
• ••The first report of the retargeting of abotulinum neurotoxin endopeptidase to achieve inhibition of secretion in alternative target cells.
   Google Scholar
• CHADDOCK JA, PURKISS JR, DUGGAN MJ et al.: A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors (2000) 18:147–155.
   PubMed Web of Science ®Google Scholar
• SOLLNER TSW, WHITEHEART M, BRUNNER H et al.: SNAP receptors implicated in vesicle targeting and fusion. Nature (1993) 362:318–324.
   PubMed Web of Science ®Google Scholar
• ••Seminal paper describing SNARE proteinfunction in secretion.
   Google Scholar
• STREIT WJ, SCHULTE BA, BALENTINE DJ, SPICER SS: Histochemical localization of galactose-cotaining glycoconjugates in sensory neurons and their processes in the central and peripheral nervous system of the rat. Histochem. Cytochem. (1985) 33:1042–1052.
   PubMed Web of Science ®Google Scholar
• STREIT WJ, SCHULTE BA, BALENTINE DJ, SPICER SS: Evidence for glyco conjugate in nociceptive primary sensory neurons and its origin from the Golgi complex. Broth Res (1986) 377:1–17.
   PubMed Web of Science ®Google Scholar
• DUGGAN MJ, QUINN CP, CHADDOCK JA, PURKISS JR et al: Inhibition of release of neurotransmitters from dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagallilectin. J. Biol. Chem. (2002) 277(38):34846–34852. First report of the generation of a conjugate protein containing the endopeptidase of BoNT/A specifically targeting primary nociceptive afferent neurons.
   Google Scholar
• CHADDOCK JA, PURKISS JR, ALEXANDER FCG et al.: Retargeted clostridial endopeptidases: inhibiiton of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov. Disord. (2004) 19\(Suppl. 8):542–547.
   Google Scholar
• ••First demonstration that a conjugateprotein containing the endopeptidase of BoNT/A displays prolonged analgesic activity in animal models of pain.
   Google Scholar
• KELLER JE, NEALE EA, OYLER G, ADLER M: Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. (1999) 456(1):137–142.
   PubMed Web of Science ®Google Scholar
• KELLER JE, NEALE EA: The role of the synaptic protein SNAP-25 in the potency of botulinum neurotoxin type A. I Biol. Chem. (2001) 276(16):13476–13482.
   Web of Science ®Google Scholar
• FERNANDEZ-SALAS E, STEWARD LE, HO H et al: Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc. Nat. Acad. Li. USA (2004) 101(9):3208–3213.
   PubMed Web of Science ®Google Scholar
• DOLLY 0: Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache (2004) 43\(Suppl. 1):516–524.
   Google Scholar
• AOKI KR, RUBINO J, KHANIJOU S et al: Retargeted clostridial endopeptidase: antinociceptive activity in in vivo models of pain. International Association for the Study of Pain, 10th World Congress on Path San Diego, CA, USA (2002) (Abstract 831).
   Google Scholar
• LACY DB, TEPP W, COHEN AC et al: Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. (1998) 5:898–902.
   PubMedGoogle Scholar